Lisette Hilton
Lisette Hilton is president of Words Come Alive, based in Boca Raton, Florida.
'Dr. Scar' shares treatment pearls
A U.S. dermatologist shares his experience working with a Chinese plastic surgeon who does a high-volume of scar treatments.
FDA approves corticosteroid-sparing topical option for eczema
The FDA announced it has approved Eucrisa (Anacor Pharmaceuticals, crisaborole) ointment to treat mild to moderate eczema in patients two-years-of-age and older.
Responding to melanoma’s growing threat
Melanoma’s burden is increasing and the rising rates cannot simply be attributed to increased disease detection, according to a research letter published last month in JAMA Dermatology.
Motivating teens not to tan, on teens’ terms
You might be surprised about what researchers have uncovered about why teens tan. Having a better understanding of their motives, could help you help them.
How the Trump presidency may impact dermatology
Dermatology’s leaders share perspectives on how the new Administration may impact medicine.
Dermatology’s 2017 Game Changers
Several dermatologists go over what they're most excited about to see in 2017 in a number of different topics ranging from AD treatment to off-label technology use, to more male patients.
Study offers new insight into pediatric eczema
Researchers have identified the skin phenotype of pediatric atopic dermatitis (AD) — a finding that challenges the notion of filaggrin's central role in the disease.
Derms likely to misdiagnose fungal infections on visual inspection
A recent survey asking dermatologists to visually determine whether clinical photos are or aren’t fungal infections suggests visual inspection might not be enough for accurate diagnoses.
National hospital initiative targets preventable injuries
Unintentional injury is ranked number one among the 10 leading causes of death in children. In fact, injuries, ranging from car and bike crashes to poisonings and gunshot wounds, kill more children than anything else, starting at age 1 year to age 44 years.
Phase 3 results demonstrate dupilumab efficacy
New data suggests positive safety and efficacy profile. Further studies need to assess long-term use.

Poll

View Results